AIDS malignancies represent an increasing cause of morbidity and mortality for persons with HIV infection. For example, in both the ACTG 019 trial and in the Concorde trial, malignancies accounted for over 25% of the study endpoints in these asymptomatic, HIV infected populations. In the ACTG 196 trial, a trial in very advanced patients, malignancies accounted for over 23% of the deaths. Clearly, as patients with HIV infection live longer, malignant complications will become more frequent and more devastating. Fortunately, there has been substantial progress in our understanding of the pathogenesis of several AIDS related malignancies. The improved basic science understanding has provided many new leads for drug development. It is hypothesized that a systematic evaluation of the multiple new therapeutic opportunities will result in a significant increase in the life expectancy for patients with HIV infection. UCLA has been at the fore front in the battle against AIDS and its malignant complications. UCLA was one of the first to have a malignancy clinic and continues to have one of the largest Kaposi sarcoma clinics in the world. Basic scientists at UCLA have contributed significantly to our understanding of this disease and AIDS related lymphomas. Clinicians at UCLA have designed, enrolled and completed many important trials in AIDS related malignancies. Investigators at UCLA have a particular expertise in the use of cytokines and immune modulators. This application proposes to utilize the combined talents of two investigators with an extensive experience in the treatment of AIDS malignancies. It will take advantage of our experience in cooperative group trials such as the AIDS Clinical Trials Group. It will also use the AIDS Malignancy Bank that is located at UCLA. The contribution of UCLA to the overall effort of the AIDS Malignancy Clinical Trials Consortium will advance our understanding and the treatment of these diseases.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01CA070080-04
Application #
2748845
Study Section
Special Emphasis Panel (SRC (09))
Project Start
1995-09-30
Project End
1999-07-31
Budget Start
1998-08-01
Budget End
1999-07-31
Support Year
4
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of California Los Angeles
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
119132785
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Lin, Lan; Lee, Jeannette Y; Kaplan, Lawrence D et al. (2009) Effects of chemotherapy in AIDS-associated non-Hodgkin's lymphoma on Kaposi's sarcoma herpesvirus DNA in blood. J Clin Oncol 27:2496-502
Noy, Ariela; von Roenn, Jamie; Politsmakher, Alex et al. (2007) Fatal hepatorenal failure and thrombocytopenia with SU5416, a vascular endothelial growth factor Flk-1 receptor inhibitor, in AIDS-Kaposi's sarcoma. AIDS 21:113-5
Krown, Susan E; Lee, Jeannette Y; Lin, Lan et al. (2006) Interferon-alpha2b with protease inhibitor-based antiretroviral therapy in patients with AIDS-associated Kaposi sarcoma: an AIDS malignancy consortium phase I trial. J Acquir Immune Defic Syndr 41:149-53
Dezube, Bruce J; Krown, Susan E; Lee, Jeannette Y et al. (2006) Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi's sarcoma: an AIDS Malignancy Consortium Study. J Clin Oncol 24:1389-94
Epeldegui, Marta; Widney, Daniel P; Martinez-Maza, Otoniel (2006) Pathogenesis of AIDS lymphoma: role of oncogenic viruses and B cell activation-associated molecular lesions. Curr Opin Oncol 18:444-8
Kaplan, Lawrence D; Lee, Jeannette Y; Ambinder, Richard F et al. (2005) Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood 106:1538-43
Noy, Ariela; Scadden, David T; Lee, Jeannette et al. (2005) Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study Team. J Clin Oncol 23:990-8
Amado, Rafael G; Mitsuyasu, Ronald T; Rosenblatt, Joseph D et al. (2004) Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study: myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients. Hum Gene Ther 15:251-62
Miles, Steven A; Dezube, Bruce J; Lee, Jeannette Y et al. (2002) Antitumor activity of oral 9-cis-retinoic acid in HIV-associated Kaposi's sarcoma. AIDS 16:421-9
Cianfrocca, Mary; Cooley, Timothy P; Lee, Jeannette Y et al. (2002) Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study. J Clin Oncol 20:153-9

Showing the most recent 10 out of 17 publications